NCT03889938

Brief Summary

  1. 1.Assess the level of lipid mediators in patients with psoriasis
  2. 2.Assess the urinary level of biopyrins as New marker of oxidative stress in patients with psoriasis
  3. 3.Correlate the serum level of bioactive lipid mediators and urinary level of biopyrins with Psoriasis Area and Severity Index

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Apr 2019

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 22, 2019

Completed
4 days until next milestone

First Posted

Study publicly available on registry

March 26, 2019

Completed
6 days until next milestone

Study Start

First participant enrolled

April 1, 2019

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2020

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2020

Completed
Last Updated

March 26, 2019

Status Verified

March 1, 2019

Enrollment Period

1 year

First QC Date

March 22, 2019

Last Update Submit

March 24, 2019

Conditions

Psoriasis

Outcome Measures

Primary Outcomes (1)

  • the serum level of bioactive lipid mediators in patients with psoriasis

    Bioactive lipid mediators (LMs) are potent compounds reported to play a role in the development and resolution of inflammation.

    1 month

Interventions

Serum and urinary assessmentDIAGNOSTIC_TEST

Assess bioactive lipid mediators in blood and biopyrins in urine

Eligibility Criteria

Age12 Years - 80 Years
Sexall
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

All patients with psoriasis

You may qualify if:

  • age from12 to 80 and both sex

You may not qualify if:

  • patients with other dermatological disorders

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (2)

  • Sorokin AV, Domenichiello AF, Dey AK, Yuan ZX, Goyal A, Rose SM, Playford MP, Ramsden CE, Mehta NN. Bioactive Lipid Mediator Profiles in Human Psoriasis Skin and Blood. J Invest Dermatol. 2018 Jul;138(7):1518-1528. doi: 10.1016/j.jid.2018.02.003. Epub 2018 Feb 15.

    PMID: 29454560BACKGROUND

  • Bakry OA, El Hefnawy S, Mariee AH, El Gendy Y. Urinary Biopyrrins: A New Marker of Oxidative Stress in Psoriasis. Indian J Dermatol. 2016 Mar-Apr;61(2):169-73. doi: 10.4103/0019-5154.177756.

    PMID: 27057016BACKGROUND

MeSH Terms

Conditions

Psoriasis

Condition Hierarchy (Ancestors)

Skin Diseases, PapulosquamousSkin DiseasesSkin and Connective Tissue Diseases

Central Study Contacts

Shimaa Mahrous

CONTACT

01011845338shimaamahrous9@gmail.com

Eman Kamal, Ass prof

CONTACT

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal investigator

Study Record Dates

First Submitted

March 22, 2019

First Posted

March 26, 2019

Study Start

April 1, 2019

Primary Completion

April 1, 2020

Study Completion

May 1, 2020

Last Updated

March 26, 2019

Record last verified: 2019-03